CureVac Shareholders Face Pivotal Takeover Vote
Published on 11/17/2025 at 19:00 | Redaktion boerse-global.de
The fate of German biotech firm CureVac hangs in the balance as shareholders prepare for a landmark decision that could transfer control to industry giant BioNTech. With a critical vote scheduled for late November, investors are weighing whether the proposed acquisition represents their best outcome or if the competitive landscape has already been decided.
On November 25, 2025, CureVac’s extraordinary general meeting will see shareholders decide on the complete acquisition by BioNTech. The proposed terms offer approximately $5.46 per CureVac share, protected against BioNTech stock fluctuations through a specialized collar mechanism. This arrangement provides price stability regardless of market movements in BioNTech’s valuation leading up to the transaction’s completion.
The Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
